
Our aim was to zzso in patients with solid tumors, the zzso zzso maximum tolerated dose zzso and pharmacology of zzso a new zzso zzso A zzso that blocked circulating zzso growth factors in animal studies and exhibited an zzso effect in zzso solid zzso In a Phase I study, zzso was administered zzso every 6 zzso Included were patients with solid zzso an Eastern Cooperative Oncology Group performance score zzso and normal bone zzso zzso and liver functions and blood zzso zzso Excluded were patients with brain zzso or on steroid zzso zzso was scored with the National Cancer Institute Common zzso zzso Plasma and urine zzso was measured for zzso zzso The effect of zzso on serum basic zzso growth factor zzso was measured by sandwich zzso zzso patients zzso age, 54 years; range, zzso years; 19 males and 10 zzso median performance score zzso 1) were treated at dose levels of zzso zzso We observed, during 47 treatment cycles, erratic but zzso decreases of zzso III levels zzso at all dose zzso Other zzso tests remained normal except during zzso zzso zzso toxicity was zzso pulmonary zzso and grade 3 zzso zzso disappeared from the zzso decreasing zzso with a long terminal zzso of 1 zzso No significant change in zzso and no objective tumor responses were zzso Disease stabilization was achieved in four zzso In conclusion, the zzso of zzso was zzso zzso zzso zzso level was not affected by zzso up to the zzso 

